Printer Friendly

INAMED Corp. and Genzyme Surgical Products Sign Distribution Agreement.

SANTA BARBARA, Calif.--(BUSINESS WIRE)--May 14, 1999--

INAMED Corp. (OTC BB:IMDC) and Genzyme Surgical Products Friday announced an agreement under which INAMED International Corp., an INAMED Corp. business unit, will distribute Genzyme's Snowden Pencer plastic surgery product line in five Western European countries.

The agreement covers Holland, France, Spain, Germany and the United Kingdom. Genzyme Surgical Products will continue to distribute its plastic surgery product line throughout the remainder of Europe using its existing distribution system.

"This agreement will strengthen our position in the rapidly growing plastic surgery market by giving us access to an established, specialized sales force," said Michael Lacey, Genzyme's vice president of plastic surgery products. "Our customers will benefit by having INAMED's highly trained and well-regarded sales force providing them with Snowden Pencer products."

INAMED International Corp. President and Chief Executive Officer Ken Pearce commented: "We are extremely pleased to add the well-respected Snowden Pencer plastic surgery product line to our growing array of value-added products that we are able to offer to the aesthetic medical community.

"The complementary nature of this alliance is demonstrated by each company's focus on precision breast surgery. The Snowden Pencer Tebbetts(TM) breast instrument set was designed to be used in conjunction with our most advanced technology style 410 cohesive gel breast implant."

Inamed is a global surgical and medical device company engaged in the development, manufacturing and marketing of medical devices for the plastic and reconstructive, bariatric and general surgery markets. INAMED manufactures and markets a variety of implantable products for plastic surgery procedures under the McGhan brand name.

The McGhan brand is universally recognized as the technology and market-leading name in implants for breast surgery. INAMED is collaborating to develop an array of novel human-based, tissue-engineering products for aesthetic and certain reconstructive applications.

Genzyme Surgical Products, a business unit of Genzyme General, markets instruments and devices for plastic, cardiovascular and general surgery. Genzyme's Snowden Pencer brand instruments have earned a reputation for quality.

Genzyme is also a leader in the development of biomaterials for adhesion prevention and is working to establish Seprafilm(R) Bioresorbable Membrane as the standard of care in colorectal surgeries. In addition, Genzyme Surgical Products is developing gene and cell therapy products to treat cardiovascular disease.

Genzyme's releases are available at http://www.genzyme.com and on the company's fax-on-demand service at 800/436-1443 in the United States or 201/521-1080 elsewhere.

INAMED's releases are available at http://www.inamedcorp.com and http://www.mcghan.com.
COPYRIGHT 1999 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1999, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:May 14, 1999
Words:413
Previous Article:Pinkerton Acquires Aegis Protective Services, Ft. Lauderdale-based Security Firm.
Next Article:Cleveland Indians Baseball Company, Inc. Reports Seasonal First-Quarter Loss In Line With Expectations.
Topics:


Related Articles
INAMED reports first-quarter results; sales rise 29 percent; profitability down as a result of continuing breast implant litigation.
INAMED Corp. Reports That 30-Day Appeal Period on Breast Implant Litigation Settlement Has Run.
INAMED and NovaMed Announce Agreement to Increase Worldwide Sales of Breast Implant Products.
Inamed Announces Second-Quarter Results; Updates 2001 Outlook.
Inamed Corp. Announces Organizational Restructuring; Company Also Reports Mid-Quarter Sales Figures.
Gyrus ENT and Genzyme Biosurgery Complete Broad Distribution Agreement.
Inamed Provides Earnings Guidance for 2002.
Inamed, Ipsen Announce Plans to Develop Botox Competitor in Facial Aesthetics.
BRIEFCASE SCENIC WILL LEAVE AIRPORT IN MARCH.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters